drugset
drugset / Trial / NCT02182453

Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers

NCT02182453 ↗

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 10773 administered to healthy Japanese male subjects with single rising oral doses (1, 5, 10, 25, and 100 mg).

Timeline

Start
2008-06
Primary completion
2008-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 1 mg Oral
Subject Empagliflozin Small molecule 5 mg Oral
Subject Empagliflozin Small molecule 10 mg Oral
Subject Empagliflozin Small molecule 25 mg Oral
Subject Empagliflozin Small molecule 100 mg Oral

Indications

No indication recorded.